[Therapy of gastrointestinal disorders due to oral rheumatism therapy. Effect of bromopride on antirheumatic agent-induced functional reduction in the gastric mucosa barrier].
Non-steroid antirheumatic agents inhibit the synthesis of prostaglandins to an extent which depends upon their respective chemical composition. The result of this inhibition is a reduction in gastric mucosal perfusion, a limitation of cytoprotective factors, and an enhanced back diffusion of H+-ions into the mucosal cell. The function of the gastric mucosal barrier is restricted and a reduction in the measurable electric potential between the gastric serosa and mucosa ensues. Adjunctive therapy with bromopride (Cascapride) improves this reduction in gastric potential difference induced by the antirheumatic agent, and alleviates the gastrointestinal symptoms brought on by the antirheumatic drug.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D006801:Humans; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; C013855:bromopride; D008787:Metoclopramide
Zur Therapie gastrointestinaler Beschwerden bei oraler Rheuma- Behandlung. Einfluss von Bromoprid auf die Antirheumatika-induzierte Funktionseinschränkung der Magenmukosa-Schranke.